# Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

> **NCT05953545** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)**

## Conditions studied

- Chronic Hepatitis Delta

## Interventions

- **DRUG:** Peginterferon Lambda

## Key facts

- **NCT ID:** NCT05953545
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-22
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-05-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study closure based on decision of the PI
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953545, "Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05953545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*